Mary Tadros, MD
Endocrinology, Diabetes & Metabolism · Evansville, INNPI 1164425591
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 344 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,360 and has fallen 94.3% since, to $78 in 2025.
Across 344 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$756
- Abbott$606
- Novo Nordisk$558
- Insulet Corporation$505
- Amgen$374
- Medtronic$346
- plus $3K from 31 others
What the payments were for
- Food & beverage$5,68297%
- Education$1432%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 44 | $756 |
| Abbott | 45 | $606 |
| Novo Nordisk | 36 | $558 |
| Insulet Corporation | 22 | $505 |
| Amgen(2 entities) | 23 | $374 |
| Medtronic(2 entities) | 17 | $346 |
| Mannkind Corporation | 16 | $290 |
| Dexcom, Inc. | 15 | $265 |
| AbbVie | 17 | $236 |
| Sanofi-aventis U.S. LLC | 11 | $171 |
| Novartis | 10 | $169 |
| Tandem Diabetes Care, Inc. | 6 | $143 |
| Boehringer Ingelheim | 10 | $141 |
| Amryt Pharma Holdings Ltd | 7 | $128 |
| Johnson & Johnson(2 entities) | 3 | $124 |
| Xeris Pharmaceuticals, Inc. | 5 | $112 |
| AstraZeneca(2 entities) | 6 | $98 |
| Esperion Therapeutics, Inc. | 6 | $98 |
| Antares Pharma, Inc. | 6 | $90 |
| Corcept Therapeutics | 5 | $77 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Recordati_rare_diseases_inc. | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $52 |
| Radius Health, Inc. | 3 | $51 |
| Ultragenyx Pharmaceutical Inc. | 2 | $48 |
| Eisai Inc. | 2 | $40 |
| Bayer | 2 | $38 |
| Amneal Pharmaceuticals LLC | 2 | $35 |
| Lifescan, Inc. | 2 | $33 |
| Shire North American Group Inc | 2 | $32 |
| Zealand Pharma US, Inc. | 2 | $30 |
| Pfizer | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Nevro Corp. | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$125
- Minimed 630G$121
How this compares
$5,885 in reported general payments places this provider in the 70th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
See all endocrinology, diabetes & metabolism providers in Indiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 119 | $202,743 |
| MounjaroTirzepatide | 79 | $112,011 |
| JardianceEmpagliflozin | 82 | $93,188 |
| FarxigaDapagliflozin Propanediol | 50 | $51,908 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $39,787 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $36,043 |
| TradjentaLinagliptin | 32 | $31,652 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $28,497 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $26,377 |
| TrulicityDulaglutide | 15 | $26,295 |
| JanuviaSitagliptin Phosphate | 28 | $23,819 |
| Humalog Kwikpen U-100Insulin Lispro | 50 | $22,051 |
| SynthroidLevothyroxine Sodium | 170 | $17,662 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 67 | $16,312 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $12,126 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $558 | $212,046136 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $756 | $151,511130 claims |
| Boehringer IngelheimJardiance, Tradjenta | $141 | $124,840114 claims |
| AstraZenecaFarxiga | $98 | $51,90850 claims |
| AbbVieSynthroid, Armour Thyroid | $236 | $19,695184 claims |
| Sanofi-aventis U.S. LLCLantus | $171 | $3,87315 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $35 | $2,463371 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 134 endocrinology, diabetes & metabolism providers in Indiana.
Other endocrinology, diabetes & metabolism in Evansville
- Khalid ZarugEvansville$8K
- Yousef AltowairebEvansville$3K
- Isaiah PittmanTerre Haute$1.5M
- Ernest AsamoahIndianapolis$959K
- Erica KretchmanRichmond$609K
- Emily VeenemanSeymour$583K
- Nihad MuhrezMerrillville$271K
- Hisham AllababidiIndianapolis$195K
- Neha GavinFishers$149K
- Edward RicoTerre Haute$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.